Company CanBas Co., Ltd.

4575

JP3244570002

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-06-10 am EDT			5-day change	1st Jan Change
500 ^JPY	-0.40%		+0.60%	-47.92%

2023	CanBas Co., Ltd.(TSE:4575) added to S&P Global BMI Index	CI
2023	CanBas Co., Ltd. announced that it has received ¥748.0425 million in funding	CI

CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).

Number of employees: 12

Managers	Title	Age	Since
Takumi Kawabe FOU	Founder	65	00-01-17
Makoto Katozumi DFI	Director of Finance/CFO	60	00-08-31
Kazuyoshi Sakamoto ADM	Chief Administrative Officer	61	08-11-30
Toshiyuki Hibino CTO	Chief Tech/Sci/R&D Officer	47	20-06-30
Kyoko Matsuzaki BRD	Director/Board Member	74	03-08-31

Members of the board	Title	Age	Since
Takumi Kawabe FOU	Founder	65	00-01-17
Makoto Katozumi DFI	Director of Finance/CFO	60	00-08-31
Kyoko Matsuzaki BRD	Director/Board Member	74	03-08-31
Akira Shirakawa BRD	Director/Board Member	68	06-02-28
Toshio Furuta BRD	Director/Board Member	62	07-08-31
Toshiyuki Hibino CTO	Chief Tech/Sci/R&D Officer	47	20-06-30
Kazuyoshi Sakamoto ADM	Chief Administrative Officer	61	08-11-30
Yasuyuki Komiyama BRD	Director/Board Member	65	16-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	18,023,655	17,455,589 ( 96.85 %)	598 ( 0.003318 %)	96.85 %

Name	Equities	%	Valuation
Akira Nishimura 1.886 %	340,000	1.886 %	1 M ¥
Estate of Sakae Tsurumi 1.193 %	215,000	1.193 %	696 396 ¥
Estate of Tadashi Morimura 0.5548 %	100,000	0.5548 %	323 905 ¥
Estate of Takara Yoshida 0.5121 %	92,300	0.5121 %	298 964 ¥
Toshio Furuta 0.2497 %	45,000	0.2497 %	145 757 ¥
Takumi Kawabe 0.1054 %	19,000	0.1054 %	61 542 ¥
Akira Shirakawa 0.0799 %	14,400	0.0799 %	46 642 ¥
Makoto Katozumi 0.0505 %	9,100	0.0505 %	29 475 ¥
Yasuyuki Komiyama 0.0416 %	7,500	0.0416 %	24 293 ¥
CANBAS CO., LTD. 0.003262 %	588	0.003262 %	1 905 ¥

Name	Equities	%	Valuation
CANBAS CO., LTD. 0.00%	588	0.00%	1,905 $

CanBas Co., Ltd.

2-2-1 Otemachi

410-0801, Numazu

http://www.canbas.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CANBAS CO., LTD.	-47.92%	57.78M
MERCK KGAA	+18.88%	80.5B
KYOWA KIRIN CO. LTD.	+15.08%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-14.14%	4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.39%	4.49B
YUHAN CORPORATION	+18.90%	4.44B
INDIVIOR PLC	+7.93%	2.19B
BETTA PHARMACEUTICALS CO., LTD.	-28.40%	2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.93%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.17%	1.78B

Specialty & Advanced Pharmaceuticals